Literature DB >> 21947754

Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy.

Yuji Kadoi1, Hiroko Hoshi, Akiko Nishida, Shigeru Saito.   

Abstract

PURPOSE: This study was conducted to compare recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex with succinylcholine during electroconvulsive therapy (ECT).
METHODS: Seventeen patients who were scheduled to undergo ECT were studied. Anesthesia was induced by use of propofol (1.0 mg/kg) followed by either succinylcholine (SCC) (1 mg/kg) or rocuronium (0.6 mg/kg). Assisted mask ventilation was initiated with 100% oxygen. After T1 was assessed as being zero by neuromuscular monitoring, an electroshock stimulus was applied bilaterally. Patients receiving rocuronium were infused with 16, 8, or 4 mg/kg sugammadex immediately after the seizure stopped to reverse the muscle relaxation. Neuromuscular monitoring was continued until recovery of the train-of-four ratio to 0.9 at the tibial nerve in the leg. The times to recovery of T1 to 10 and 90% with both relaxants were compared.
RESULTS: The time to recovery of T1 to 90% after 16 mg/kg sugammadex was shorter than that in subjects treated with SCC (p = 0.046), whereas that after 4 mg/kg sugammadex was longer than that in subjects treated with SCC (SCC group: 429 ± 65 s, 16 mg/kg sugammadex group: 387 ± 63 s*, 8 mg/kg sugammadex group: 462 ± 66 s, 4 mg/kg sugammadex group: 563 ± 45 s(*,#); *p < 0.05 compared with SCC, (#)p < 0.01 compared with 16 mg/kg sugammadex).
CONCLUSIONS: This study demonstrates the efficacy of rocuronium-sugammadex as an alternative to SCC for muscle relaxation during ECT, and indicates that 8 mg/kg sugammadex produces equally rapid recovery from rocuronium muscular relaxation compared with spontaneous recovery from 1 mg/kg SCC during ECT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947754     DOI: 10.1007/s00540-011-1236-y

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  16 in total

1.  Rapacuronium: an alternative to succinylcholine for electroconvulsive therapy.

Authors:  A G Kadar; B A Kramer; M C Barth; P F White
Journal:  Anesth Analg       Date:  2001-05       Impact factor: 5.108

2.  [Anesthetic management for electroconvulsive therapy in the patients with a history of neuroleptic malignant syndrome].

Authors:  Keiko Setoyama; Takao Hirata; Hitoshi Saeki; Yasuhiro Morimoto; Syunsuke Tsuruta; Mishiya Matsumoto; Takefumi Sakabe
Journal:  Masui       Date:  2009-05

3.  First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.

Authors:  Francois Gijsenbergh; Steven Ramael; Natalie Houwing; Thijs van Iersel
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

4.  Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.

Authors:  Chingmuh Lee; Jonathan S Jahr; Keith A Candiotti; Brian Warriner; Mark H Zornow; Mohamed Naguib
Journal:  Anesthesiology       Date:  2009-05       Impact factor: 7.892

5.  [Effects of anesthetic agents on seizure duration and hemodynamics in electroconvulsive therapy].

Authors:  Misuzu Nishiyama; Hideaki Togashi
Journal:  Masui       Date:  2009-10

Review 6.  Goodbye suxamethonium!

Authors:  C Lee
Journal:  Anaesthesia       Date:  2009-03       Impact factor: 6.955

7.  A cross-over, post-electroconvulsive therapy comparison of clinical recovery from rocuronium versus succinylcholine.

Authors:  Deniz Cihan Turkkal; Necati Gokmen; Aysegul Yildiz; Leyla Iyilikci; Erol Gokel; Kemal Sagduyu; Ali Gunerli
Journal:  J Clin Anesth       Date:  2008-12       Impact factor: 9.452

8.  Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.

Authors:  Friedrich K Pühringer; Christopher Rex; Andreas W Sielenkämper; Casper Claudius; Per Bo Larsen; Martine E Prins; Matthias Eikermann; Karin S Khuenl-Brady
Journal:  Anesthesiology       Date:  2008-08       Impact factor: 7.892

9.  Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?

Authors:  D Kelly; S J Brull
Journal:  Can J Anaesth       Date:  1994-09       Impact factor: 5.063

10.  Relationship between cardiac output and onset of succinylcholine chloride action in electroconvulsive therapy patients.

Authors:  Naoki Matsumoto; Akihiro Tomioka; Tomonobu Sato; Masakazu Kawasaki; Yuji Kadoi; Shigeru Saito
Journal:  J ECT       Date:  2009-12       Impact factor: 3.635

View more
  4 in total

1.  Comparison between succinylcholine and rocuronium as neuromuscular blocking agents for electroconvulsive therapy in a patient with pseudocholinesterase deficiency.

Authors:  Tomonori Takazawa; Takashi Suto; Masako Aihara; Takeshi Anzai; Tatsuo Horiuchi; Makiko H Yamada; Yuji Kadoi; Shigeru Saito
Journal:  JA Clin Rep       Date:  2015-08-27

2.  The Effects of Rocuronium-sugammadex on Fetomaternal Outcomes in Pregnancy Undergoing Electroconvulsive Therapy: A Retrospective Case Series and Literature Review.

Authors:  Mahmut A Karahan; Evren Büyükfırat; Orhan Binici; Hacer Uyanıkoğlu; Adnan Incebıyık; Mehmet Asoğlu; Nuray Altay
Journal:  Cureus       Date:  2019-06-03

3.  The Use of Succinylcholine in Brugada Syndrome: A Case Report and Discussion of Literature.

Authors:  Marcus M de Wolf; Nellie M Rus; Guus H Beljaars; Hanno L Tan
Journal:  Case Rep Anesthesiol       Date:  2019-10-27

Review 4.  Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.

Authors:  Stefan Josef Schaller; Heidrun Fink
Journal:  Core Evid       Date:  2013-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.